Researchers have found that a newer group of migraine medications may offer better relief and fewer side effects than many traditional treatments for chronic migraine.
The findings come from a large scientific review published in the journal Annals of Internal Medicine. The review analyzed 43 clinical trials involving adults who experienced chronic migraine, a condition defined as headaches occurring on at least 15 days each month.
Migraine is one of the most common neurological disorders worldwide. Unlike ordinary headaches, migraines often involve severe throbbing pain along with symptoms such as nausea, vomiting, light sensitivity, sound sensitivity, and visual disturbances.
For people with chronic migraine, the condition can become physically and emotionally exhausting. Frequent migraine attacks may interfere with work, school, family life, sleep, and mental health.
Doctors have used many different medications over the years to help prevent migraines, but treatment results can vary greatly from person to person.
The new review suggests that medications targeting a protein called CGRP may currently offer the best balance between effectiveness and tolerability.
CGRP stands for calcitonin gene-related peptide. Scientists have discovered that this protein becomes highly active during migraine attacks.
When CGRP levels rise, it helps trigger inflammation and pain signals in the nervous system, contributing to migraine symptoms.
The newer migraine medications are specifically designed to block CGRP activity or prevent it from binding to receptors in the body.
By interrupting this process, the drugs may help reduce the number and severity of migraine attacks.
The study was led by Malahat Khalili from the Michael G. DeGroote Institute for Pain Research and Care at McMaster University in Canada.
Researchers reviewed 43 clinical trials involving different migraine prevention treatments.
Among all the therapies studied, the strongest evidence supported CGRP-targeted drugs.
Patients using these medications experienced about two fewer migraine days each month on average compared with placebo treatment.
Researchers say this reduction can still be very meaningful for people living with headaches most days of the month.
The review also found that the newer drugs generally caused fewer side effects than older migraine medications.
Examples of CGRP-targeted therapies include eptinezumab, sold under the brand name Vyepti, and atogepant, known as Qulipta.
One advantage of these newer medications is that they come in different forms, including injections, intravenous infusions, tablets, and nasal sprays. This gives patients and doctors more flexibility when choosing treatment options.
The researchers also evaluated botulinum toxin therapy, commonly called Botox.
Botox has been used for years to help prevent chronic migraine attacks. The treatment involves injections that may reduce pain signaling and muscle tension associated with migraines.
According to the review, Botox may still provide benefits for some patients. However, the evidence supporting Botox was less certain compared with the newer CGRP-targeted medications.
The researchers also found that side effects and treatment discontinuation were more common with Botox.
Older migraine prevention medications such as topiramate, valproate, and propranolol were also included in the analysis.
These drugs have long been used for migraine prevention because they affect brain signaling, blood pressure, or nerve activity.
However, the review found that the scientific evidence supporting these older medications was weaker and less consistent.
In addition, many patients experience side effects that can make long-term treatment difficult. Some common side effects may include tiredness, dizziness, concentration problems, weight changes, or mood effects.
The researchers caution that although the newer CGRP therapies appear promising, more long-term studies are still needed.
Because these drugs are relatively new, scientists still need to monitor how patients respond over many years and whether any rare side effects appear with prolonged use.
The review also highlights the importance of cost and access.
Some of the newer migraine medications can be expensive, and insurance coverage may not always be available. For this reason, treatment decisions often depend not only on medical effectiveness but also on affordability and patient preference.
Researchers emphasize that migraine treatment should be personalized.
What works extremely well for one patient may not work for another. Doctors often need to consider migraine severity, medical history, side effects, convenience, and patient lifestyle when choosing treatment plans.
Experts encourage patients with chronic migraine to discuss all available treatment options with their healthcare providers.
The findings from this large review suggest that CGRP-targeted therapies may represent an important step forward in migraine care and could improve quality of life for many patients who struggle with frequent headaches.
If you care about arthritis, please read studies about extra virgin olive oil for arthritis, and pomegranate: A natural treatment for rheumatoid arthritis.
For more information about arthritis, please see recent studies about how to live pain-free with arthritis, and results showing medical cannabis may help reduce arthritis pain, back pain.
The study findings were published in Annals of Internal Medicine.
Source: McMaster University.
